May 8-13, 2016
Biosimilars promise to increase access to life-saving and life-enhancing therapeutics, while creating cost savings that can fund further innovations in health care. Achievement of these goals is critically dependent on acceptance by prescribing physicians. This session will explore the following questions: What do clinicians care about? What do they know about the manufacture and characterization of biosimilars? What should they know? These questions will be addressed in the context of specific examples arising in the development of biosimilars to Neupogen, Infliximab, Humira, and Rituximab.
Jan Hillson, "Cell culture engineering and biosimilars: The physician’s perspective" in "Cell Culture Engineering XV", Robert Kiss, Genentech Sarah Harcum, Clemson University Jeff Chalmers, Ohio State University Eds, ECI Symposium Series, (2016). http://dc.engconfintl.org/cellculture_xv/34